Printer Friendly

Protective Effect of a Polyherbal Aqueous Extract Comprised of Nigella sativa (Seeds), Hemidesmus indicus (Roots), and Smilax glabra (Rhizome) on Bleomycin Induced Cytogenetic Damage in Human Lymphocytes.

1. Introduction

Chemotherapy is one of the treatment modalities that arrests growth of malignancy either by killing transformed cells or by arresting their division. Chemotherapy is often used either as adjuvant or neoadjuvant or in conjunction with radiotherapy and surgery. However, the major drawback of using such cancer therapeutics is that it may lead to transient and/or permanent damage to normal tissues due to their direct toxicity to healthy cells or toxicity mediated by signals generated by target cancer cells [1, 2]. Nausea, vomiting, diarrhoea, inflammation of the intestinal and oral mucosa, loss of appetite, fatigue, anaemia, leukopenia, pain, and initiation of secondary neoplastic changes are some of the common symptoms of toxicities during cancer chemotherapy [3-6]. Generation of free radicals and initiation of uncoordinated inflammatory response are some of the principle mechanisms of toxicities derived from cancer chemotherapy or radiotherapy [7-10]. Bleomycin (BLM), a commonly used anticancer drug, has been reported to exert free radical mediated toxic effects in similar manner to that of ionized radiation (IR) [11]. BLM induces DNA strand breaks, resulting in production of DNA adducts and excess reactive oxygen species (ROS) leading to oxidative stress, mitochondrial leakage, and apoptosis [12]. Bleomycin at a concentration of 40 [micro]g/mL can induce radiomimetic damage equal to 2 Gy of gamma radiation which is the standard fraction applied daily to cancer patients in fractionation regimes used in radiotherapy [13].

Natural antioxidants have been considered to be promising protective agents against free radical mediated damage induced during cancer therapy. A number of effective compounds such as hoechst [14], cysteine [15], caffeine [16], calcium channel blockers [17], flavonoids [18], and 2-deoxyD-glucose [19] have been identified. Natural antioxidants have also demonstrated effective protection against ROS mediated cellular damage during cancer chemotherapy and radiotherapy [20-22]. However, there are comparatively few investigations that investigate the use of natural protectors during chemotherapy and/or radiotherapy. The importance of such protectors is emerging due to frequent use of chemotherapeutics in combinational therapy with radiation, causing higher magnitude of toxicity than either of the above two modes of therapy.

Polyherbal decoction comprised of Nigella sativa seeds, Hemidesmus indicus roots, and Smilax glabra rhizome in equal proportions has traditionally been used by a particular family of Ayurvedic physician in Sri Lanka to treat cancer patients [23]. Recent studies have demonstrated that the above decoction can provide significant protection against chemically induced hepatocarcinogenic changes in rats [24] without producing any significant toxic effects and exert cytotoxicity in human hepatoma (HepG2) cells [25]. Protection against oxidative damage [26], favourable immune modulation [27], and expression and suppression of proapoptotic and antiapoptotic genes [28] are some of the mechanisms which mediate anticancer activity of the decoction. It was hypothesized that the claimed antioxidant activity of the decoction may play a dual role: (a) protecting healthy cells against the damage mediated by either chemotherapy or radiotherapy and (b) restricting the tumour progression by resisting mutation in cancer management.

Therefore, the present study was carried out with the primary objective of evaluating the effectiveness of the decoction comprised of N. sativa seeds, H. indicus roots, and S. glabra rhizome, in protecting against bleomycin induced cytogenetic damage in peripheral blood lymphocytes (PBLs).

2. Materials and Methods

2.1. Plant Material. Seeds of N. sativa (Ranunculacaea), roots of H. indicus (Asclepiadaceae), and rhizome of S. glabra (Smilacaceae) were purchased and authenticated by the botanist at the Bandaranayaks Memorial Ayurvedic Research Institute (BMARI), Nawinna, Maharagama, Sri Lanka. Voucher specimens (UKFM/B/2006/01, UKFM/B/2006/02, and UKfM/B/2006/03) have been deposited at the Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Sri Lanka.

2.2. Preparation of Standardized Decoction. Standardized decoction was prepared as previously described by Samarakoon et al. [28]. Equal portions (20 g each) of N. sativa (seeds), H. indicus (roots), and S. glabra (rhizome) were mixed and boiled gently in 1.6 L of distilled water until a final volume of 200 mL was obtained. The extract was then filtered, freeze dried, and stored in a vacuum desiccator at -4[degrees]C. The percentage yield of the freeze dried plant material was 13.6%. For experimental purposes, the required weight of the freeze dried powder was reconstituted in 1% dimethyl sulfoxide (DMSO) and filter sterilized using 0.22 [micro]m disposable filters.

2.3. Blood Sample Collection. Study was approved and carried out according to the guidelines of Ethical Review Committee, Sri Ramachandra University, Chennai, India. Heparinized blood samples (~10 mL) were obtained with informed consent and according to institutional procedures from six healthy donors aged 24-34 years, without any history of smoking, tobacco chewing, or alcohol consumption, and they were not taking any drugs for medical or other reasons.

2.4. Experimental Design. Out of 10 mL of blood collected from each individual, equal volume of 4 mL was used for chromosome aberration (CA) studies and cytokinesis-blocked micronuclei (CBMN) assay while the remaining blood was used for [gamma]-H2AX assay. For each CA and CBMN assays, 4 mL of blood was reconstituted with 36 mL of RPMI1640 culture medium supplemented with 7.5% NaHCO3, 20% fetal calf serum, 200 mM L-glutamine, penicillin (100 units/mL), and streptomycin (100 [micro]g/mL) and equally aliquoted into eight sterile vials. Two sets of vials (each set consisting of three vials) were added with the decoction at concentrations of 100, 300, and 600 [micro]g/mL. Each set of vials served as decoction control and the test, respectively. All vials were then incubated at 37[degrees]C in 5% C[O.sub.2] for 3 hrs. At the end of the 3rd hour, bleomycin at a concentration of 40 [micro]g/mL was added to (a) a one set of vials containing three different doses of the decoction and (b) a vial without the decoction (bleomycin control) and all were further incubated for 2 hrs. A vial with addition of neither decoction nor bleomycin served as negative control. After 5 hrs of incubation, cells in each vial were washed with Hanks Balanced Salt Solution (HBSS) three times. Each sample was then reconstituted in 4.5 mL of culture medium (RPMI-1640) and used for CA and CBMN analysis as described below.

For [gamma]-H2AX assay, remaining 2 mL of blood was reconstituted with 18 mL of RPMI-1640 culture medium and equally aliquoted into four sterile vials. Decoction at a concentration of 100 [micro]g/mL was then added to two vials (decoction control and test) and all vials were incubated at 37[degrees]C in 5% C[O.sub.2] for 3 hrs. At the end of the 3rd hour, bleomycin at a concentration of 40 [micro]g/mL was added to (a) a vial containing the decoction (test) and (b) a vial without the decoction (positive control). Subsequently, all vials were incubated for further 2 hrs and lymphocytes were isolated by layering 4 mL aliquot from each vial on to 2mL of Histopaque-1077 and centrifuged at 1000g for 5 min at room temperature.

2.5. Processing of Cultures for Chromosomal Aberration. Lymphocyte cultures for chromosomal aberration assay were processed as described earlier [29]. Briefly, cultures were initiated by adding 0.2 mL of phytohemagglutinin into each vial containing 0.5 mL of blood and 4.5 mL of RPMI-1640 supplemented with 7.5% NaHCO3, 20% fetal calf serum, 200 mM L-Glutamine, penicillin (100 units/mL), and streptomycin (100 [micro]g/mL) and incubated at 37[degrees]C in 5% C[O.sub.2]. At 46th hour of incubation, the cells were blocked at metaphase by adding colcemid at a final concentration of 0.1 [micro]g/mL and the cultures were further incubated until 48hrs. The samples were then harvested after hypotonic treatment (20 minutes with 0.45% KCl at 37[degrees]C), washed three times with Carnoy's fixative, and cast on clean precooled slides. All slides were stained with 10% Giemsa, air-dried, and mounted with cover-slip using DPX mounting medium to analyze the chromosomal aberrations.

2.6. Processing of Cultures for CBMN Assay. Lymphocyte cultures for micronuclei assay were set up according to method described by Fenech and Morley [30]. Briefly, cultures were initiated as described in chromosomal aberration assay and at the end of 44th hour of culture Cytochalasin-B at a final concentration of 3 [micro]g/mL culture was added to each vial. The cells were further incubated for 28 hrs at 37[degrees]C. The cells were harvested with brief hypotonic treatment and slides were prepared by fixing the cells with Carnoy's fixative. The cell suspensions were dropped onto a clean cooled slide and stained with Giemsa.

2.7. Lymphocyte Preparation for [gamma]-H2AX Foci Assay. Isolated lymphocytes were spotted onto microscope slides (six slides/each individual) at an optimized cell density for immunofluorescence staining. Cells were fixed in 3.7% paraformaldehyde in PBS (15 min at room temperature) and permeabilised using 0.5% Triton X100 in PBS (5 min at 4[degrees]C). Samples were blocked in phosphate buffered saline (PBS) with 2% bovine serum albumin (BSA) for 3 x 5 min at room temperature. Samples were then incubated with anti-[gamma]-H2AX antibody (clone JBW301) overnight at 4[degrees]C, and washed in PBS, 2% BSA, for 2 x 5 min. Finally slides were incubated with FITC-conjugated goat anti-mouse secondary antibody (Invitrogen, Paisley, UK) for 1h at room temperature. Slides were washed in PBS for 2 x 2 min, stained with 4,6-diamidino-2phenylindole (DAPI) for 5 min, washed for 2 min in PBS, and mounted using Mowiol Mounting Medium.

2.8. Slide Scoring. For cytogenetic analysis, preparations were coded and scored blind by two examiners. Chromosomal aberrations were analyzed in 100 metaphase spreads for each individual. Cells were analyzed for chromosome and chromatid types of aberrations as described earlier [31].

Scoring of MN was limited to binucleate (BL) lymphocytes only with preserved cytoplasm according to the criteria proposed by Fenech et al. [32]. Identification of binucleate cells in cell groups required careful visual examination of the individual cell boundaries. The results are expressed as number of micronucleated cells per 1000 binucleate cells on the two different slides from the same culture. Proliferation kinetics data was calculated by considering the frequencies of mono-, di-, tri-, and tetranucleate cells per each treatment group. A nuclear division index (NDI) was calculated according to the formula proposed by Takeshita et al. [33] as follows: NDI = (1[M.sub.1] + 2[M.sub.2] + 3[M.sub.3] + 4[M.sub.4])/N, where [M.sub.1] to [M.sub.4] represent the number of cells with one to four nuclei and N is the total number of cells scored.

For the viewing of [gamma]-H2AX immunofluorescence foci, an epifluorescence microscope (ProvisAX70, Olympus) was used. Fields were initially selected at 10x on the basis of DAPI counterstained nuclei. Acquired DAPI image was used to define the focusing area and the detection of foci was performed using 40x objectives at optimized detection parameters. Scoring of foci was carried out manually in double blinded manner.

2.9. Statistical Analysis. From the various types of aberration recorded the aberration frequency was calculated as follows:

Aberration Frequency = Number of aberrations observed per sample/Number of metaphases scored per sample. (1)

The standard error for the aberration frequency was calculated as follows:

Standard error = [square root of (Number of aberrations observed per sample/Number of metaphases scored per sample)]. (2)

Multiple comparisons between different experimental groups were done using multifactor ANOVA.

3. Results

3.1. Effects on Chromosomal Aberration. Dicentric chromosomes (DC), acentric fragments (AF), and chromatid breaks (ChB) were the indices used to evaluate the chromosomal aberrations during the present study. The results of unstable chromosomal aberrations in the four experimental groups are summarized in Table 1. The baseline chromosomal damage of the negative control was negligible (DC = 0.037, AF = 0.043, and ChB = 0.063) and was comparable to that in published literature. Further, it was observed that there was no significant change in chromosomal aberrations due to introduction of the decoction at the dose range of 100-600 [micro]g/mL.

Chromosomal aberrations in bleomycin control were significantly high when compared with the negative control. On exposure to bleomycin, there was a 7-fold increase in the frequency of cells with dicentrics (0.27 per 100 cells) when compared to the index in negative control group (0.037 per 100 cells). The increases observed in AF (8-fold increase) and ChB (7-fold increase) were similar to that observed with respect to DC. In the test cells (lymphocytes exposed to bleomycin plus the decoction) there was a significant reduction (p < 0.05) in chromosomal damage when compared with the bleomycin control. The reductions in DC, AF, and ChB at the decoction dose of 300 [micro]g/mL were nearly 2-fold that of the bleomycin control. The maximum percentage of inhibitions for DC (48%), AF (47%), and ChB (37%) was observed at the decoction dose of 300 [micro]g/mL. However, a slight deterioration in the protection was observed at a decoction dose of 600 [micro]g/mL (Table 1).

3.2. Effects on Cytokinesis-Blocked Micronuclei (CBMN) Formation. Prevalence of MN in four experimental groups is illustrated in Table 2. The mean MN frequency in control PBLs was 10 MN per 1000 binucleated cells. Similar to effect in chromosomal aberration study, the decoction by itself did not induce any excess MN. A slight statistically insignificant elevation in MN count was observed in PBLs exposed to the decoction (100-600 [micro]g/mL), with respect to the control samples. These results suggest that the decoction at a concentration range of 100-600 [micro]g/mL does not induce any significant damage to lymphocyte genome in vitro.

As expected nearly 9-fold increase in MN (89 MN per 1000 binucleated cells) was observed in lymphocytes exposed to bleomycin for 2 hrs at a dose of 40 [micro]g/mL (equal to that of 2 Gy of gamma radiation). This increase was consistent in all three subjects tested.

Bleomycin induced damage was significantly reduced (p < 0.05) in lymphocytes preexposed to the decoction at the tested dose range. Overall reduction was nearly 72% (25 MN per 1000 binucleated cells) when compared with the bleomycin control (88 MN per 1000 binucleated cells). This result suggests a significant protective effect of the decoction against genomic damage induced by bleomycin.

Nuclear division index (NDI) was calculated to assess the effects of the decoction on the proliferative capacity of lymphocytes. NDI in lymphocytes treated with the decoction is same as that of control, suggesting no interference of the decoction in human lymphocyte proliferation. However, a significant delay in lymphocyte proliferation in the presence of bleomycin at a concentration of 40 [micro]g/mL was observed. This was manifested by a change in relative numbers of M1 to [M.sub.4] cells. However, restoration of NDI was observed in lymphocytes pretreated with the decoction prior to bleomycin induction. This reflects a successful overcome of cytotoxic effects caused by bleomycin, by modulating the lymphocyte proliferation.

3.3. Effects on Formation of [gamma]-H2AX Foci. The effect of the decoction on bleomycin induced [gamma]-H2AX foci in peripheral lymphocytes is illustrated in Figure 1 and Table 3. Baseline DNA damage in the present study was at 0.11 [+ or -] 0.04 foci per cell, represented by 674 cells without a single foci and 218 and 108 cells with single and double foci, respectively. None of the control cells indicated more than two (2) foci within a cell. Decoction by itself (at a concentration of 100 [micro]g/mL) did not induce any significant DNA damage, as it indicated 0.14[+ or -]0.06 foci per cells with a distribution at 0-2 foci per cell. This observation is compatible with the previous results of MN and CA assays. Bleomycin (40 [micro]g/mL), an equal dose to 2 Gy irradiation, significantly induced [gamma]-H2AX foci (3.16 [+ or -] 1.13), with a distribution range of 0-10 foci per cell. Out of 1000 cells analyzed, approximately 700 cells were bearing either 2, 3, or 4 foci per cell. This was compatible with previous reports on lymphocytes exposed to 2 Gy irradiation.

It was interesting to observe a significant reduction in [gamma]-H2AX yield in lymphocytes exposed to bleomycin (40 [micro]g/mL) pretreated with the decoction at a dose of 100 [micro]g/mL. The number of foci per cell stood at 2.42 [+ or -] 1.01 foci within the range of 0-9 foci per cell. However, majority of cells (approx. 600 cells) indicated either 0,1, or 2 foci per cell while 340 cells were reported to contain 3 foci per cell. The present results further confirm the ability of the decoction to protect against cytogenetic damage mediated by irradiation.

4. Discussion

A wide variety of chemotherapeutic agents are used routinely in clinical oncology. These therapies can also lead to cytotoxic and genotoxic effects in normal cells of the body, in addition to their effects on tumour cells [1, 3]. Any agent that could modulate such toxicity to normal cells would therefore be of much value in reducing the very unpleasant side effects experienced by cancer patients receiving chemotherapy.

It is well documented that bleomycin, like most other chemotherapeutic drugs, can mediate DNA changes in both cancer cells and normal cells. As with ionizing radiation, Bleomycin mediates its genotoxic effects by inducing DNA double strand breaks (dsbs) which is one of the critical lesions for cellular death [11]. This "radiomimetic" agent induces such double strand breaks by highly specific, concerted free radical attack on deoxyribose moieties in both DNA strands [33, 34]. Although the lesion induced by bleomycin is supposed to be only a small subset of the many lesions induced by ionizing radiation, effects of this radiomimetic agent in cells are remarkably similar to those of ionizing radiation [35].

The present investigation has shown that the decoction comprised of N. sativa seeds, H. indicus roots, and S. glabra rhizomes can significantly protect against bleomycin induced (a) chromosomal aberrations, (b) formation of micronuclei, and (c) DNA dsbs in normal human peripheral blood lymphocytes. Decoction itself induces no significant chromosomal aberrations, no micronuclei formation, nor DNA dsbs in lymphocytes.

Nuclear Division Index (NDI) is calculated to assess the effects of decoction on the proliferative capacity of human lymphocytes [36]. From NDI values calculated in the present investigation, it was apparent that bleomycin caused a delay in cell proliferation, manifested by a change in relative numbers of cells with one nucleus to cells with four nuclei (M1 to M4 cells). The NDI values in lymphocytes exposed to bleomycin alone are similar to those reported by other investigators [37]. In general, different types of ionizing radiation delay lymphocyte cell cycle and the extent of such delay depends on the dose delivered. An average mitotic delay of about 1 h per 1 Gy of gamma radiation has been observed once lymphocytes are exposed to ionizing radiation [38]. These delays in cell cycle allow the cell to repair DNA and try to reduce the adverse effects of the irradiation [39]. Normalization of NDI in bleomycin exposed lymphocytes that are previously treated with the decoction supports the protection mediated by the decoction against radiation induced damage.

Antioxidant activity is considered to be one of the major mechanisms by which many plants and phytochemicals are reported to offer radioprotection [40]. The potent antioxidant compounds present in the decoction may therefore be mainly responsible for the protective effect demonstrated by this herbal drug against bleomycin induced DNA damage in normal peripheral lymphocytes. The antioxidant potency of this polyherbal preparation is probably due to the collective contribution of antioxidant compounds present in the individual plant components used in its preparation. Thus, previous in vivo studies demonstrate that N. sativa seed oil can significantly reduce blood oxidative stress markers of rats exposed to a single dose of 6 Gy radiation [41]. Similarly, extracts of H. indicus that can protect against radiation induced strand breaks in plasmid DNA have also been shown to protect against oxidative stress induced lipid peroxidation [42]. Although these studies demonstrate the ability of the individual plants in the decoction to reduce oxidative stress, none of them have evaluated the ability of these plants to protect against cytogenetic damage induced by chemotherapy alone or in combination with radiotherapy.

Since the polyherbal decoction under current investigation consists of a number of active ingredients, previously reported multimechanistic approach of the decoction in counteracting tumour progression can reasonably be justified. Counteract to oxidative stress is one of such mechanisms that may render a resistance to chemotherapy or radiotherapy in malignant cells, but effective in protecting healthy cells during the said treatment modalities. However, such compromised anticancer activity of the decoction will be well compensated by the existence of the remaining anticancer mechanisms of the decoction.

In conclusion, the present investigation indicates that the decoction comprised of N. sativa seeds, H. indicus roots, and S. glabra rhizomes has the potential to protect against cytogenetic damage inflicted by bleomycin in human peripheral lymphocytes. Since the decoction under current investigation has previously been reported to mediate anticancer effect against certain malignancies, the observed radioprotective potential has a definite clinical advantage during its use among cancer patients. Thus, it could protect the patient against radiation induced cell damage while restricting tumour progression.

In the present investigation, the effect of the decoction was evaluated at a single preincubation period of 3 hrs. However, the in-cooperation of different preincubation periods may have a significant impact on the claimed radioprotective potential of the decoction under current investigation. Despite these limitations, the findings of the present study clearly indicate the broad functional spectrum of the decoction comprised of N. sativa seeds, H. indicus roots, and S. glabra rhizomes in cancer management.

Conflicts of Interest

There are no financial or personal interests that might pose a conflict.


The authors are grateful to Dr. U. B. N. Baranedharan (Department of Human Genetics, SRU, Chennai, India) for his technical assistance. This work is supported by financial grants provided by India-Sri Lanka Foundation, High Commission of India, Colombo, Sri Lanka.


[1] K. Lotfi-Jam, M. Carey, M. Jefford, P. Schofield, C. Charleson, and S. Aranda, "Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review," Journal of Clinical Oncology, vol. 26, no. 34, pp. 5618-5629, 2008.

[2] B. J. Monk, H. Q. Huang, D. Cella, H. J. Long III., and D. Mackey, "Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study," Journal of Clinical Oncology, vol. 23, no. 21, pp. 4617-4625, 2005.

[3] E. G. Vichaya, G. S. Chiu, K. Krukowski et al., "Mechanisms of chemotherapy-induced behavioral toxicities," Frontiers in Neuroscience, vol. 9, article 131, 2015.

[4] K. Bergkvist and Y. Wengstrom, "Symptom experiences during chemotherapy treatment--with focus on nausea and vomiting," European Journal of Oncology Nursing, vol. 10, no. 1, pp. 21-29, 2006.

[5] P. Nieboer, C. Buijs, S. Rodenhuis et al., "Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: A Longitudinal Study," Journal of Clinical Oncology, vol. 23, no. 33, pp. 8296-8304, 2005.

[6] J. E. Groopman and L. M. Itri, "Chemotherapy-induced anemia in Adults: incidence and treatment," Journal of the National Cancer Institute, vol. 91, no. 19, pp. 1616-1634, 1999.

[7] H. Hug, S. Strand, A. Grambihler et al., "Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells," The Journal of Biological Chemistry, vol. 272, no. 45, pp. 28191-28193, 1997.

[8] S. N. Giri, M. A. Al-Bayati, X. Du, E. Schelegle, F. C. Mohr, and S. B. Margolin, "Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats," Cancer Chemotherapy and Pharmacology, vol. 53, no. 2, pp. 141-150, 2004.

[9] J. Tangpong, M. P. Cole, R. Sultana et al., "Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain," Journal of Neurochemistry, vol. 100, no. 1, pp. 191-201, 2007

[10] I. GulQn, V. Mshvildadze, A. Gepdiremen, and R. Elias, "Antioxidant activity of saponins isolated from ivy: [alpha]-Hederin, hederasaponin-C, hederacolchiside-E and hederacolchiside-F," Planta Medica, vol. 70, no. 6, pp. 561-563, 2004.

[11] A. Mira, E. M. Gimenez, A. D. Bolzan, M. S. Bianchi, and D. M. Lopez-Larraza, "Effect of thiol compounds on bleomycininduced DNA and chromosome damage in human cells," Archives of Environmental and Occupational Health, vol. 68, no. 2, pp. 107-116, 2013.

[12] J. Dresp, E. Schmid, and M. Bauchinger, "The cytogenetic effect of bleomycin on human peripheral lymphocytes in vitro and in vivo," Mutation Research--Fundamental and Molecular Mechanisms of Mutagenesis, vol. 56, no. 3, pp. 341-353, 1978.

[13] J. Sanchez, M. S. Bianchi, and A. D. Bolzan, "Effect of bleomycin on interstitial telomeric sequences of immortalized Chinese hamster ovary cells," Mutation Research--Fundamental and Molecular Mechanisms of Mutagenesis, vol. 669, no. 1-2, pp. 139-146, 2009.

[14] L. Denison, A. Haigh, G. D'Cunha, and R. F. Martin, "DNA ligants as radio protectors: molecular studies with hoechst 3342 and hoechst 33258," Internation Journal of Radiation Biology, vol. 61, no. 1, pp. 69-81, 2009.

[15] H. M. Patt, E. B. Tyree, R. L. Straube, and D. E. Smith, "Cysteine protection against X irradiation," Science, vol. 110, no. 2852, pp. 213-214, 1949.

[16] A. Franchitto, P. Pichierri, P. Mosesso, and F. Palitti, "Caffeine effect on the mitotic delay induced by G2 treatment with UVC or mitomycin C," Mutagenesis, vol. 13, no. 5, pp. 499-505, 1998.

[17] R. Varshney and R. K. Kale, "Modulation of radiation induced lipid peroxidation by phospholipase A2 and calmodulin antagonists: Relevance to detoxification," Radiation Physics and Chemistry, vol. 45, no. 4, pp. 671-675, 1995.

[18] R. J. Nijveldt, E. Van Nood, D. E. Van Hoorn, P G. Boelens, K. Van Norren, and P A. Van, "A review of probable mechanisms of action and potential applications," American Journal of Clinical Nutrition, vol. 74, pp. 418-425, 2001.

[19] V. k. Jain, V. K. Kalia, P M. Gopinath, S. Naqvi, and K. Kucheria, "Optimization of cancer therapy: Part III-Effect of combining 2deoxy-D-glucose treatment with gamma-irradiation on normal mice," Indian Journal of Experimental Biology, vol. 20, pp. 1320-1325, 1979.

[20] S. V. Gudkov, I. N. Shtarkman, V S. Smirnova, A. V. Chernikov, and V. I. Bruskov, "Guanosine and inosine display antioxidant activity, protect DNA in vitro from oxidative damage induced by reactive oxygen species, and serve as radioprotectors in mice," Radiation Research, vol. 165, no. 5, pp. 538-545, 2006.

[21] D. K. Maurya, T. P A. Devasagayam, and C. K. K. Nair, "Some novel approaches for radioprotection and the beneficial effect of natural products," Indian Journal of Experimental Biology, vol. 44, no. 2, pp. 93-114, 2006.

[22] R. Arora, R. Chawla, S. C. Puri et al., "Radioprotective and antioxidant properties of low-altitude Podophyllum hexandrum (LAPH)," Journal of Environmental Pathology, Toxicology and Oncology, vol. 24, no. 4, pp. 299-314, 2005.

[23] S. R. Samarakoon, I. Thabrew, P B. Galhena, and K. H. Tennekoon, "Effect of standardized decoction of Nigella sativa seed, Hemidesmus indicus root and smilax glabra rhizome on the expression of p53 and p21 genes in human hepatoma cells (HepG2) and mouse liver with chemically-induced hepatocarcinogenesis," Tropical Journal of Pharmaceutical Research, vol. 11, no. 1, pp. 51-61, 2012.

[24] S. S. Iddamaldeniya, M. I. Thabrew, S. M. D. N. Wickramasinghe, N. Ratnatunge, and M. G. Thammitiyagodage, "A long-term investigation of the anti-hepatocarcinogenic potential of an indigenous medicine comprised of Nigella sativa, Hemidesmus indicus and Smilax glabra," Journal of Carcinogenesis, vol. 5, article 11, 2006.

[25] M. I. Thabrew, R. R. Mitry, M. A. Morsy, and R. D. Hughes, "Cytotoxic effects of a decoction of Nigella sativa, Hemidesmus indicus and Smilax glabra on human hepatoma HepG2 cells," Life Sciences, vol. 77, no. 12, pp. 1319-1330, 2005.

[26] B. P Galhena, M. I. Thabrew, M. Tammitiyagodage, and V. A. H. Rachel, "Anti-hepatocarcinogenicAyurvedic herbal remedy reduces the extent of diethylnitrosamine-induced oxidative stress in rats," PhcogMag, vol. 4, no. 17, pp. 19-27, 2005.

[27] P B. Galhena, S. R. Samarakoon, M. I. Thabrew et al., "Antiinflammatory activity is a possible mechanism by which the polyherbal formulation comprised of Nigella sativa (seeds), Hemidesmus indicus (root), and Smilax glabra (rhizome) mediates its antihepatocarcinogenic effects," Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 108626, 11 pages, 2012.

[28] S. R. Samarakoon, I. Thabrew, P. B. Galhena, D. De Silva, and K. Tennekoon, "A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of Nigella sativa (seeds), Hemidesmus indicus (roots) and Smilax glabra (rhizome)," Pharmacognosy Research, vol. 2, no. 6, pp. 335-342, 2010.

[29] IAEA Technical Report, Biological Dosimetry, Chromosomal Aberration Analysis for Dose Assessment, vol. 20 of Technical report series, IAEA, Vienna, Austria, 1986.

[30] M. Fenech and A. A. Morley, "Measurement of micronuclei in lymphocytes," Mutation Research--Genetic Toxicology and Environmental Mutagenesis, vol. 147, no. 1-2, pp. 29-36, 1985.

[31] D. W. Bleyl, Methods for the Analysis of Human Chromosome Aberrations, vol. 19, WHO Report, Geneva, Switzerland, 1973.

[32] M. Fenech, W. P. Chang, M. Kirsch-Volders, N. Holland, S. Bonassi, and E. Zeiger, "HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures," Mutation Research, vol. 534, no. 1-2, pp. 65-75, 2003.

[33] M. Takeshita, A. P Grollman, E. Ohtsubo, and H. Ohtsubo, "Interaction of bleomycin with DNA," Proceedings of the National Academy of Sciences, vol. 75, no. 12, pp. 5983-5987, 1978.

[34] E. A. Sausville, J. Peisach, and S. B. Horwitz, "A role for ferrous ion and oxygen in the degradation of DNA by bleomycin," Biochemical and Biophysical Research Communications, vol. 73, no. 3, pp. 814-822, 1976.

[35] L. F. Povirk, "DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: Bleomycin, neocarzinostatin and other enediynes," Mutation Research--Fundamental and Molecular Mechanisms of Mutagenesis, vol. 355, no. 1-2, pp. 71-89, 1996.

[36] K. Maria, "Thiamine prevents X-ray induction of genetic changes in human lymphocytes in vitro," ActaBiochimicaPolonica, vol. 51, no. 3, pp. 839-843, 2004.

[37] A. P Krishnaja and N. K. Sharma, "Variability in cytogenetic adaptive response of cultured human lymphocytes to mitomycin C, bleomycin, quinacrine dihydrochloride, Co60 y-rays and hyperthermia," Mutagenesis, vol. 23, no. 2, pp. 77-86, 2008.

[38] R. J. Purrott, N. Vulpis, and D. C. Lloyd, "The use of harlequin staining to measure delay in the human lymphocyte cell cycle induced by in vitro X-irradiation," Mutation Research--Fundamental and Molecular Mechanisms of Mutagenesis, vol. 69, no. 2, pp. 275-282, 1980.

[39] N. Cheong, Z. C. Zeng, Y. Wang, and G. Iliakis, "Evidence for factors modulating radiation-induced G2-delay: potential application as radioprotectors," PhysicaMedica, vol. 17, no. 1, pp. 205-209, 2001.

[40] S. V. Gudkov, I. N. Shtarkman, V. S. Smirnova, A. V. Chernikov, and V. I. Bruskov, "Guanosine and inosine as natural antioxidants and radioprotectors for mice exposed to lethal doses of y-radiation," Doklady Biochemistry and Biophysics, vol. 407, no. 1, pp. 47-50, 2006.

[41] M. Cemek, H. Enginar, T. Karaca, and P Unak, "In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats," Photochemistry and Photobiology, vol. 82, no. 6, pp. 1691-1696, 2006.

[42] T. K. Shetty, J. G. Satav, and C. K. K. Nair, "Radiation protection of DNA and membrane in vitro by extract of Hemidesmus indicus," Phytotherapy Research, vol. 19, no. 5, pp. 387-390, 2005.

Bandula Prasanna Galhena, (1) S. S. R. Samarakoon, (2) Myrtle Ira Thabrew, (2) Solomon F. D. Paul, (3) Venkatachalam Perumal, (3) and Chinnadurai Mani (4)

(1) Department of Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka

(2) Institute of Biochemistry, Molecular Biology, and Biotechnology, University of Colombo, Colombo, Sri Lanka

(3) Department of Human Genetics, Sri Ramachandra University, Chennai, India

(4) Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Correspondence should be addressed to Bandula Prasanna Galhena;

Received 31 January 2017; Revised 4 April 2017; Accepted 16 April 2017; Published 25 May 2017

Academic Editor: Blanca Laffon

Caption: Figure 1: Mean number of [gamma]-H2AX foci observed in lymphocytes obtained from four (4) experimental groups. Data represents mean [+ or -] SD of six samples from each experimental group.
Table 1: Mean numbers of various chromosomal aberrations after damage
induced by bleomycin (40 [micro]g/mL) in the presence or absence of
the decoction (100/600 [micro]g/mL). DC, dicentric chromosome; AF,
acentric fragments; ChB, chromatid breaks.

Experimental         Concentration
groups               ([micro]g/mL)     DC per 100 spreads

Negative control                      0.037 [+ or -] 0.01

                        Dec. 100      0.027 [+ or -] 0.01
Decoction control         300         0.026 [+ or -] 0.01
                          600         0.029 [+ or -] 0.02

Bleomycin control        BLM 40        0.27 [+ or -] 0.04
                         BLM 40
Test (decoction +       Dec. 100       0.17 [+ or -] 0.04
bleomycin)                300          0.14 [+ or -] 0.03
                          600          0.16 [+ or -] 0.01

Experimental         Concentration        DC%
groups               ([micro]g/mL)     inhibition

Negative control

                        Dec. 100
Decoction control         300

Bleomycin control        BLM 40
                         BLM 40
Test (decoction +       Dec. 100         37.03
bleomycin)                300            48.15
                          600            40.74

Experimental         Concentration           AF per
groups               ([micro]g/mL)            100

Negative control                      0.043 [+ or -] 0.01

                        Dec. 100      0.057 [+ or -] 0.01
Decoction control         300         0.049 [+ or -] 0.02
                          600         0.054 [+ or -] 0.01

Bleomycin control        BLM 40        0.36 [+ or -] 0.02
                         BLM 40
Test (decoction +       Dec. 100       0.23 [+ or -] 0.02
bleomycin)                300          0.19 [+ or -] 0.01
                          600          0.21 [+ or -] 0.02

Experimental         Concentration        AF%
groups               ([micro]g/mL)     inhibition

Negative control

                        Dec. 100
Decoction control         300

Bleomycin control        BLM 40
                         BLM 40
Test (decoction +       Dec. 100         36.11
bleomycin)                300            47.23
                          600            41.67

Experimental         Concentration            ChB
groups               ([micro]g/mL)          per 100

Negative control                      0.063 [+ or -] 0.01

                        Dec. 100      0.043 [+ or -] 0.02
Decoction control         300         0.041 [+ or -] 0.01
                          600         0.047 [+ or -] 0.02

Bleomycin control        BLM 40        0.46 [+ or -] 0.04
                         BLM 40
Test (decoction +       Dec. 100       0.34 [+ or -] 0.03
bleomycin)                300          0.29 [+ or -] 0.02
                          600          0.33 [+ or -] 0.01

Experimental         Concentration        ChB%
groups               ([micro]g/mL)     inhibition

Negative control

                        Dec. 100
Decoction control         300

Bleomycin control        BLM 40
                         BLM 40
Test (decoction +       Dec. 100          26.1
bleomycin)                300            36.96
                          600            28.26

Table 2: The effect of the decoction at a dose range of100-600
[micro]g-mL on micronuclei induction in vitro by bleomycin (40
[micro]g-mL) in cultured human lymphocytes. The values are mean
[+ or -] SD per 1000 binucleated cells per individual of a sample
population of 6 individuals. Nuclear division index (NDI) was
expressed as mean [+ or -] SD for each experimental groups.

Experimental          Concentrations            MN/1000 BL
groups                   (Eg/mL)            (mean [+ or -] SD)

Negative control                         0.00967 [+ or -] 0.00252

                         Dec. 100        0.01167 [+ or -] 0.00252
Decoction control          300           0.00983 [+ or -] 0.00241
                           600           0.01187 [+ or -] 0.00213

Bleomycin control         BLM 40         0.08833 [+ or -] 0.00603

                          BLM 40
Test (decoction +        Dec. 100         0.025 [+ or -] 0.00265
bleomycin)                 300            0.021 [+ or -]0.00231
                           600            0.024 [+ or -] 0.00243

Experimental          Concentrations     MN% inhibition
groups                   (Eg/mL)

Negative control

                         Dec. 100
Decoction control          300

Bleomycin control         BLM 40

                          BLM 40
Test (decoction +        Dec. 100            71.69
bleomycin)                 300               76.23
                           600               72.83

Experimental          Concentrations               NDI
groups                   (Eg/mL)            (mean [+ or -] SD)

Negative control                         1.64333 [+ or -] 0.10786

                         Dec. 100
Decoction control          300           1.66333 [+ or -] 0.10693

Bleomycin control         BLM 40         1.47667 [+ or -]0.10017

                          BLM 40
Test (decoction +        Dec. 100
bleomycin)                 300             1.6 [+ or -] 0.12166

Table 3: Number of lymphocytes bearing different number of
[gamma]-H2AX foci obtained from four (04) different experimental
groups. Total count of 1000 lymphocytes was considered per each
test group.

Experimental groups                     Number of [gamma]H2AX foci

                                        0        1        2        3

Negative control                       674      218      108       00
Decoction control (100 [micro]g/mL)    596      283      121       00
Bleomycin control (40 [micro]g/mL)      70      116      192      293
Test (decoction + bleomycin)            84      189      294      342

Experimental groups                      Number of [gamma]H2AX foci

                                        4        5        6        7

Negative control                        00       00       00       00
Decoction control (100 [micro]g/mL)     00       00       00       00
Bleomycin control (40 [micro]g/mL)     185       87       16       09
Test (decoction + bleomycin)            73       08       06       00

Experimental groups                   Number of [gamma]H2AX foci

                                        8        9        10

Negative control                        00       00       00
Decoction control (100 [micro]g/mL)     00       00       00
Bleomycin control (40 [micro]g/mL)      26       05       01
Test (decoction + bleomycin)            03       01       00
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Galhena, Bandula Prasanna; Samarakoon, S.S.R.; Thabrew, Myrtle Ira; Paul, Solomon F.D.; Perumal, Ven
Publication:BioMed Research International
Article Type:Report
Date:Jan 1, 2017
Previous Article:Imaging and Management of Incidental Renal Lesions.
Next Article:Integrating miRNA and mRNA Expression Profiling Uncovers miRNAs Underlying Fat Deposition in Sheep.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters